Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.73 |
| ▸ | HPGD | P15428 | 4/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285890 | 1.00 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL1285869 | 1.00 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL16127910 | 0.90 | ALDH1A1 (0.60) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL16088681 | 0.88 | ALDH1A1 (0.57) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL4930922 | 0.86 | ALDH1A1 (0.71) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL27651927 | 0.86 | ALDH1A1 (0.71) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL1698252 | 0.84 | L3MBTL1 (0.58) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL16348943 | 0.84 | ALDH1A1 (0.71) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL20022689 | 0.84 | ALDH1A1 (0.71) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL12461860 | 0.84 | ALDH1A1 (0.71) | ALDH1A1KDM4EHPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551465-B2 | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | CELLTRION INC. (KR) | 2026-02-17 | — | — | US | claimed |
| US-11760750-B1 | Process for preparing levoketoconazole | NURAY CHEMICALS PRIVATE LIMITED (IN) | 2023-09-19 | — | — | US | claimed |
| US-20230190708-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION | CELLTRION, INC. (KR) | 2023-06-22 | — | — | US | claimed |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | CELLTRION, INC. (KR) | 2023-04-20 | — | — | US | claimed |
| EP-4140482-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION | Celltrion, Inc. (KR) | 2023-03-01 | — | — | EP | claimed |
| CN-113718256-B | Copper etching liquid and application thereof in wafer level packaging | 浙江奥首材料科技有限公司 | 2022-11-11 | — | — | CN | claimed |
| US-20220162233-A1 | PROCESSES AND COMPOUNDS | RADIUS HEALTH, INC. | 2022-05-26 | — | — | US | claimed |
| EP-3924328-A1 | PROCESSES AND COMPOUNDS | Radius Pharmaceuticals, Inc. (US) | 2021-12-22 | — | — | EP | claimed |
| CN-113718256-A | Copper etching liquid and application thereof in wafer level packaging | 浙江奥首材料科技有限公司 | 2021-11-30 | — | — | CN | claimed |
| WO-2021215852-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION | (주)셀트리온 (KR) | 2021-10-28 | — | — | WO | claimed |
| US-20110124909-A1 | NOVEL PROCESS | GENERICS [UK] LIMITED (GB) | 2011-05-26 | — | — | US | claimed |
| EP-2324009-A1 | PROCESS FOR PREPARING CERTAIN CINNAMIDE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2011-05-25 | — | — | EP | claimed |
| US-20110009629-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | SANDOZ AG (CH) | 2011-01-13 | — | — | US | claimed |
| EP-2262761-A1 | NOVEL PROCESS | Generics [UK] Limited (GB) | 2010-12-22 | — | — | EP | claimed |
| EP-2260029-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | Sandoz AG (CH) | 2010-12-15 | — | — | EP | claimed |
| WO-2010131025-A1 | SITAGLIPTIN SYNTHESIS | GENERICS [UK] LIMITED (GB) | 2010-11-18 | — | — | WO | claimed |
| WO-2010025197-A1 | PROCESS FOR PREPARING CERTAIN CINNAMIDE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-04 | — | — | WO | claimed |
| WO-2009122215-A1 | NOVEL PROCESS | GENERICS [UK] LIMITED (GB) | 2009-10-08 | — | — | WO | claimed |
| WO-2009106486-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | SANDOZ AG (CH) | 2009-09-03 | — | — | WO | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009629-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | OPRK1, TACR1, CMA1 | ALDH1A1 1063/4885KDM4E 2781/4885HPGD 356/4885 |
| US-12551465-B2 | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | ME2, TNNT2, TNNC1 | ALDH1A1 440/4885KDM4E 1563/4885HPGD 213/4885 |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | SDHA, SDHB, ALDH5A1 | ALDH1A1 230/4885KDM4E 1130/4885HPGD 256/4885 |
| US-20110124909-A1 | NOVEL PROCESS | GABRE, GABRB2, GABRB1 | ALDH1A1 1268/4885KDM4E 1978/4885HPGD 1801/4885 |
| US-20220162233-A1 | PROCESSES AND COMPOUNDS | ESR1, ESR2, CYP19A1 | ALDH1A1 546/4885KDM4E 520/4885HPGD 580/4885 |
| US-20230190708-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION | ATP2A2, CPT1B, TNNT2 | ALDH1A1 1793/4885KDM4E 2539/4885HPGD 1156/4885 |
| US-11760750-B1 | Process for preparing levoketoconazole | KHK, KYAT3, PLK3 | ALDH1A1 2659/4885KDM4E 378/4885HPGD 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.